1/2/

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

fe Application of:

Vogels et al.

Serial No.: 10/002,750

Filed: November 15, 2001

For: COMPLEMENTING CELL LINES

Confirmation No.: 5853

Examiner: M. Burkhart

Group Art Unit: 1636

Attorney Docket No.: 2578-5148US

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail on the date of deposit shown below with sufficient postage and in an envelope addressed to the Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

June 24, 2005

Date

Betty Vo

Name (Type/Print)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

, 🚉

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

U.S. Patent Documents

U.S. Patent No.

Publication Date

Patentee

US - 2002/0177544 A1

11-28-2002

Haack et al.

Serial No.: 10/002,750

Foreign Patent Documents

Document No.	Publication Date	<u>Patentee</u>
WO 98/17783	04-30-1998	Regents of the University of
		Michigan
WO 02/40665 A2	05-23-2002	Crucell Holland B.V.
DE 197 54 103 A 1	06-10-1999	HepaVec AG
DE 199 18 023 A 1	09-21-2000	Cichon

Other Documents

PCT International Search Report, PCT/NL01/00824, dated July 19, 2002.

SCHIEDNER et al., Abstract, Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production, Human Gene Therapy, October 10, 2000, pp. 2105-16, Vol. 11. No. 15.

This Supplemental Information Disclosure Statement is believed to be filed before the mailing date of the first Office Action on the merits subsequent to the filing of an RCE in the above-identified application.

Serial No.: 10/002,750

Respectfully submitted,

Allen C. Turner

Registration No. 33,041 Attorney for Applicant(s)

TRASKBRITT, P.C.

P.O. Box 2550

Salt Lake City, Utah 84110-2550

Telephone: 801-532-1922

Date: June 24, 2005

ACT/bv

Enclosures: Form PTO/SB/08

Copy of documents cited

Document in ProLaw

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

Vogels et al.

1636

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known INFORMATION DISCLOSURE Application Number 10/002,750 November 15, 2001 Filing Date STATEMENT BY APPLICANT

First Named Inventor

Group Art Unit

(use as many sheets as necessary)

JUN 2 7 2005

M. Burkhart **Examiner Name** 2 2578-5148US Sheet of Attorney Docket Number

		Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	Cite No. ¹	Number - Kind Code ² (if known)			
		US-2002/0177544 A1	11-28-2002	Haack et al.	
		US-			

Examiner Cite Initials* No.1	Cite	Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,	
	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶	
		WO 98/17783	04-30-1998	Regents of the University of Michigan		
		WO 02/40665 A2	05-23-2002	Crucell Holland B.V.		
		DE 197 54 103 A 1	06-10-1999	HepaVec AG		Abstract
		DE 199 18 023 A 1	09-21-2000	Cichon		Abstract

	, , , , , , , , , , , , , , , , , , , ,		
Examiner Signature		Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known			
INFORMATION DISCLOSURE		Application Number	10/002,750		
			Filing Date	November 15, 2001	
STAT		NT	First Named Inventor	Vogels et al.	
			Group Art Unit	1636	
(use as many sheets as necessary)			Examiner Name	M. Burkhart	
Sheet	2	of 2		Attorney Docket Number	2578-5148US

Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		PCT International Search Report, PCT/NL01/00824, dated July 19, 2002.	
		SCHIEDNER et al., Abstract, Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production, Human Gene Therapy, October 10, 2000, pp. 2105-16, Vol. 11. No. 15.	
			-

Considered Signature

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.